Tag: Amgen

Amgen and Novartis to Stop Alzheimer’s Prevention Study

Amgen, Novartis and Banner Alzheimer's Institute have announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the...

Amgen and Allergan Introduce Two Biosimilars in the U.S.

molecule
Amgen and Allergan announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTI™ (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in th...

Amgen Update on Status of EVENITY™ in the EU

Amgen and UCB announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Mar...

Amgen and the Institute for Protein Design Announce Partnership

Amgen and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, an...

Amgen, Merck, Eli Lilly Sue the U.S. Government to Block Rule Requiring Drug Prices in TV Ads

Three pharmaceutical companies sued the federal government to block a proposal requiring drug manufacturers include the list price of prescription drugs in television ads, the latest volley by the ind...

BLINCYTO Five-Year Overall Survival Data Presented by Amgen

Amgen announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive a...

Five-Year Survival Data for Blincyto Unveiled by Amgen

amgen
Amgen has revealed “compelling” long-term survival data for its acute lymphoblastic leukemia (ALL) drug Blincyto (blinatumomab). The five-year overall survival (OS) analysis – based on data from th...

Amgen and Allergan’s Biosimilar To Herceptin Approved by FDA

Amgen and Allergan plc announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzum...

Sanofi vs Amgen Litigations over Praluent Patents in Germany

Germany’s highest civil court on Tuesday rejected French drugmaker Sanofi’s bid to fend off a legal challenge by U.S. rival Amgen against Sanofi’s cholesterol drug Praluent. In the latest setback f...

Amgen Agreed to Buy Danish Biotech Nuevolution

amgen
Amgen has agreed to buy Danish biotech Nuevolution for 1.61bn krona ($167m), three years after forging a drug discovery alliance with the company. The board of Copenhagen-based, Sweden-listed Nuevo...

Amgen Announced Precision Medicine Collaboration in Oncology with Syapse

amgen
Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precision medicine collaboration in oncology. Und...

Amgen and Astellas Agreed to Pay $125M to Settle Medicare Kickback Claims

Amgen and Astellas’ U.S. branch have agreed to pay $124.75 million to resolve allegations that they each violated the False Claims Act by illegally paying the Medicare copays for their own products, t...

Astellas, Amgen to pay $125M After Probe in Co-Payment Scheme

astellas
Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients’ out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of ...

Amgen Set the List Price for the New Osteoporosis Drug

Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections. The U.S. Food and Drug Administration last ...

FDA Approved Amgen Osteoporosis Drug

The U.S. Food and Drug Administration approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of os...

Legal Dispute between Novartis and Amgen

Novartis announced that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of termination of its migraine coll...